The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…
The National Institute of Oncology in Gliwice has launched a pioneering clinical study using a novel radiotracer for immuno-PET imaging.…
The Axcellant team recently returned from Orlando, where we attended the 30th Annual Scientific Session and Exhibition of the American…
A recent publication in npj Digital Medicine explored the use of AI-generated radiology reports — and the results are worth…
The Axcellant team recently traveled to New York to meet with research partners and clinical collaborators from across the U.S.…
Clinical trials are often seen as a regulatory necessity, but for biotech and medtech startups, they can be much more.…
Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered…
Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…
The EU is moving forward with key upgrades to its medical device and diagnostics regulations, specifically under the Medical Device…
Gene therapies now account for most ATMP clinical trials, with a balanced distribution between in vivo and ex vivo approaches.…
Academic medical centers in the US are voicing concern over reduced funding from the National Institutes of Health (NIH). While…
Robust clinical trial data are proving to be fundamental in shaping investor confidence and driving strategic decisions in the biotechnology…
Between 2015 and 2020, over 200 AI/ML-enabled medical devices received regulatory approval in the US and EU, with a strong…
In a recent article published by My Company Polska—one of Poland's leading business magazines—the untapped potential of mushrooms took center…
Axcellant is excited to announce our participation at the European Association of Nuclear Medicine (EANM) Congress in Hamburg from October…
At March’s online “Racjonalny Inwestor” conference hosted by StockWatch.pl, our CEO, Wojciech Kula, joined a panel discussion on a key…
Over the past two decades, the Polish CRO industry has transformed dramatically. What began with simple monitoring tasks has evolved…
The clinical research market in Poland has experienced remarkable growth, expanding from an estimated €200 million a decade ago to…
Marking a significant achievement in our ongoing efforts to advance medical device research, we have successfully concluded a PMCF study…
Initiating a clinical trial is akin to embarking on a voyage of discovery in the realm of medicine. This journey,…
Our team at Axcellant is proud to announce the completion of a significant Post-Market Clinical Follow-up study. This study was…
In the ever-evolving realm of pharmaceuticals and healthcare, a remarkable transformation is afoot - one that's reshaping the way we…
Clinical research is a complex and multifaceted field that relies on the dedicated efforts of a diverse team to bring…
Meet our team at top Nuclear Medicine Event – SNMMI in Chicago, 24 - 27 June 2023.
Regulators in the European Union (EU) have taken several initiatives in the past four years to increase the efficiency of paediatric regulatory processes and boost the development of medicines for children.
From 31 January 2023, all initial clinical trial applications in the European Union (EU) must be submitted via the Clinical Trials Information System (CTIS).
The European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published recommendations that aim to...
Copyright @ 2025 Axcellant